Abstract
Results of a much-anticipated comparison of 2 competing osteoporosis therapies show a significant advantage for Merck & Co.’s bisphosphonate agent alendronic acid [‘Fosamax’] over Novartis’ intranasal calcitonin [‘Miacalcin’] in postmenopausal women with osteoporosis. Treatment with alendronic acid led to greater increases in bone mineral density (BMD) in the spine, femoral neck and trochanter, compared with calcitonin. The agents had similar tolerability; in addition, the incidence of adverse events in both active therapy groups was similar to that seen in placebo recipients, as reported at the 81st Annual Meeting of the Endocrine Society [San Diego, US; June 1999].
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
